ART0380 is being developed as an oral anti-cancer agent for the treatment of patients with cancers that have defects in deoxyribonucleic acid (DNA) repair.~The study will recruit selected patients with advanced or metastatic solid tumors, specifically:~Patients with persistent or recurrent endometrial cancer (EC)~Patients with advanced or metastatic solid tumors of any histology~Above patients will be randomized in a 1:1 ratio to one of two dose regimens of ART0380.~Safety will be evaluated on a quarterly basis, at a minimum. Patients may continue to receive ART0380 as long as they are continuing to derive benefit from treatment or until disease progression, withdrawal of consent, or until they experience unacceptable drug-related toxicity.
This interventional study will evaluate the efficacy and safety of ART0380 as monotherapy in patients whose tumors have a biology to predict for sensitivity to inhibition of Ataxia-Telangiectasia Mutated and Rad3-related protein kinase (ATR).